siltuximab
patritumab
brentuximab
ocrelizumab
antimonoclonal
mepolizumab
novid
conatumumab
adebrelimab
vobarilizumab
Pfizered
perakizumab
immunofluorescence
lemalesomab
brolucizumab
ravulizumab
drozitumab
matuzumab
abagovomab
gevokizumab
tozinameran
olaratumab
pidilizumab
tislelizumab
lintuzumab
COVID-positive
double-jabbed
anti-nuclear factor
clotshot
naptumomab estafenatox
tixagevimab
onartuzumab
-lim-
brazikumab
faralimomab
precoronavirus
apolizumab
sifalimumab
coronavirus
ipilimumab
fluorescein isothiocyanate
alsevalimab
countercorrelated
teneliximab
fluorescein isocyanate
sibrotuzumab
dacetuzumab
figitumumab
cilgavimab